Karyopharm Therapeutics
(NASDAQ) KPTI
Karyopharm Therapeutics Financials at a Glance
Market Cap
$214.39M
Revenue (TTM)
$151.12M
Net Income (TTM)
-$194.97M
EPS (TTM)
-$15.09
P/E Ratio
-0.63
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Price
$10.22
Volume
32,024
Open
$9.39
Price
$10.22
Volume
32,024
Open
$9.39
Previous Close
$10.22
Daily Range
$9.39 - $10.22
52-Week Range
$3.65 - $10.99
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.27 (Average)
Price
$10.22
Volume
32,024
Open
$9.39
Previous Close
$10.22
Daily Range
$9.39 - $10.22
52-Week Range
$3.65 - $10.99
Estimated Earnings Date
Aug 10, 2026
KPTI News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Karyopharm Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
228
CEO
Richard A. Paulson, MBA
Website
www.karyopharm.comHeadquarters
Newton, MA 02459, US
KPTI Financials
Key Financial Metrics (TTM)
Gross Margin
96.03%
Operating Margin
-55.73%
Net Income Margin
-129.02%
Return on Equity
73.11%
Return on Capital
N/A
Return on Assets
-148.36%
Earnings Yield
-1.59%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$214.39M
Shares Outstanding
22.66M
Volume
32.02K
Avg. Volume
520.71K
Financials (TTM)
Gross Profit
$145.11M
Operating Income
-$84.21M
EBITDA
-$147.92M
Operating Cash Flow
-$59.11M
Capital Expenditure
$0.00
Free Cash Flow
-$59.11M
Cash & ST Invst.
$90.85M
Total Debt
$230.87M
Karyopharm Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$35.07M
+16.8%
Gross Profit
$33.71M
+17.4%
Gross Margin
96.13%
N/A
Market Cap
$214.39M
N/A
Market Cap/Employee
$768.43K
N/A
Employees
279
N/A
Net Income
-$22.39M
+4.6%
EBITDA
-$9.83M
+20.5%
Quarterly Fundamentals
Total Cash
$90.85M
+29.9%
Total Debt
$230.87M
+23.7%
Accounts Receivable
$23.36M
-33.7%
Inventory
$3.60M
-24.5%
Long Term Debt
$197.62M
+22.5%
Short Term Debt
$33.25M
+31.0%
Return on Assets
-1.48%
N/A
Return on Invested Capital
-5.97%
N/A
Free Cash Flow
-$22.73M
+41.7%
Operating Cash Flow
-$22.73M
+41.7%